Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

MLN9708 in combination with lenalidomide and dexamethasone against multiple myeloma

Dr Shaji Kumar - Mayo Clinic, Rochester, USA
MLN9708 in combination with lenalidomide and dexamethasone against multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
17 Dec 2012

PACE Trial: Phase II trial of ponatinib in patients with chronic myeloid leukaemia (CML)

Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA
PACE Trial: Phase II trial of ponatinib in patients with chronic myeloid leukaemia (CML) ( Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA )
17 Dec 2012

Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients

Professor Meletios Dimopoulos - University of Athens, Greece
Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients ( Professor Meletios Dimopoulos - University of Athens, Greece )
16 Dec 2012

MLN9708 in combination with lenalidomide and dexamethasone

Dr Shaji Kumar - Mayo Clinic, Rochester, USA
MLN9708 in combination with lenalidomide and dexamethasone ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
16 Dec 2012

History of epidermal stem cell use in the clinical setting

Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy
History of epidermal stem cell use in the clinical setting ( Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy )
14 Dec 2012

Exercise benefit to lifespan may be due to stem cell increase

Dr Mariusz Ratajczak - James Graham Brown Cancer Center, University of Louisville, Kentucky, USA
Exercise benefit to lifespan may be due to stem cell increase ( Dr Mariusz Ratajczak - James Graham Brown Cancer Center, University of Louisville, Kentucky, USA )
14 Dec 2012

Diagnosis of blood cancer after a breast cancer diagnosis

Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA
Diagnosis of blood cancer after a breast cancer diagnosis ( Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA )
14 Dec 2012

Histone deacetylases targeted as new strategy against graft versus host disease

Prof Sung Choi - University of Michigan, Ann Arbor, USA
Histone deacetylases targeted as new strategy against graft versus host disease ( Prof Sung Choi - University of Michigan, Ann Arbor, USA )
14 Dec 2012

Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA
Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia ( Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA )
13 Dec 2012

Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
13 Dec 2012

The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab

Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA
The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab ( Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2012

Uncovering new targets for treatment of chronic lymphocytic leukaemia

Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA
Uncovering new targets for treatment of chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA )
13 Dec 2012